Generation Bio Co (GBIO)
Official siteBIOTECHNOLOGY
Last updated: Feb 09, 2026 at 4:00 PM ET
Generation Bio Co (GBIO) Financials: Revenue, Profit and Cash Flow
Generation Bio reported revenue of $19.89M for the fiscal year ended Dec 31, 2024, up 236.9% from the year before. That year, net income was -$131.67M with a net margin of -661.9%, operating cash flow was -$88.56M and free cash flow was -$90.96M. The quarter ended Sep 30, 2025 had revenue of $1.59M and net income of -$5.52M.
Revenue and Margins
Over the 6 years to Dec 2024, revenue grew from $36.00K, a compound annual rate of 186.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $19.89M | +236.9% | 100.0% | -715.8% | -661.9% |
| Dec 2023 | $5.90M | N/A | 100.0% | -2346.9% | -2144.5% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2018 | $36.00K | N/A | 100.0% | -103594.4% | -99452.8% |
Income Statement
In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $19.89M | $5.90M | $0 | $0 | $0 | $0 | $36.00K |
| Gross profit | $19.89M | $5.90M | $0 | $0 | $0 | $0 | $36.00K |
| Research and development | $61.30M | $93.62M | $96.72M | $85.25M | $58.53M | $50.13M | $28.15M |
| Operating income | -$142.39M | -$138.56M | -$141.18M | -$119.10M | -$81.11M | -$62.30M | -$37.29M |
| Net income | -$131.67M | -$126.61M | -$136.64M | -$119.15M | -$80.52M | -$61.32M | -$35.80M |
| EBITDA | N/A | N/A | -$138.34M | -$114.04M | -$77.43M | -$60.76M | -$36.95M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.59M | $765.00K | $8.72M | $4.19M | $7.55M | $4.09M | $4.06M | $2.88M | $2.15M | $880.00K | $0 | $0 |
| Gross profit | $1.59M | $765.00K | $8.72M | $4.19M | $7.55M | $4.09M | $4.06M | $2.88M | $2.15M | $880.00K | $0 | -$1.35M |
| Operating income | -$6.71M | -$22.92M | -$16.61M | -$23.56M | -$17.88M | -$23.31M | -$77.63M | -$38.42M | -$31.36M | -$33.92M | -$34.87M | -$34.69M |
| Net income | -$5.52M | -$20.92M | -$14.80M | -$21.38M | -$15.31M | -$20.43M | -$74.54M | -$35.19M | -$28.27M | -$31.07M | -$32.09M | -$32.41M |
Balance Sheet
As of Dec 2024, cash and equivalents exceeded short-term debt of $13.01M by $63.30M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Total assets | $231.20M | $374.76M | $376.26M | $476.77M | $294.15M | $42.14M | $83.52M |
| Current assets | $192.90M | $272.62M | $287.02M | $379.19M | $267.74M | $18.16M | $76.93M |
| Cash and equivalents | $76.30M | $66.45M | $93.17M | $375.14M | $62.89M | $15.08M | $7.30M |
| Total liabilities | $144.99M | $171.63M | $93.77M | $95.03M | $26.14M | $25.14M | $125.11M |
| Short-term debt | $13.01M | $8.12M | $7.09M | $4.61M | $1.39M | $1.37M | N/A |
| Shareholder equity | $86.20M | $203.13M | $282.49M | $381.75M | $268.01M | -$98.59M | -$41.59M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $121.90M | $179.43M | $201.35M | $231.20M | $248.78M | $265.26M | $285.88M | $374.76M | $381.49M | $404.88M | $431.42M | $376.26M |
| Total liabilities | $71.34M | $125.33M | $128.02M | $144.99M | $144.34M | $149.86M | $153.89M | $171.63M | $149.58M | $150.60M | $152.28M | $93.77M |
| Cash and equivalents | $21.94M | $49.09M | $50.89M | $76.30M | $21.66M | $28.50M | $35.53M | $66.45M | $93.36M | $144.97M | $95.65M | $93.17M |
| Shareholder equity | $50.56M | $54.10M | $73.33M | $86.20M | $104.44M | $115.41M | $131.99M | $203.13M | $231.91M | $254.29M | $279.14M | $282.49M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$88.56M | -$52.74M | -$102.45M | -$91.82M | -$70.14M | -$40.35M | -$28.12M |
| Capital expenditures | $2.40M | $7.40M | $8.80M | $5.96M | $5.52M | $19.99M | $3.02M |
| Free cash flow | -$90.96M | -$60.14M | -$111.25M | -$97.78M | -$75.66M | -$60.33M | -$31.14M |
| Share repurchases | $0 | $164.00K | $50.00K | $955.00K | $3.23M | $22.00K | N/A |
| Investing cash flow | $94.53M | -$9.70M | -$192.51M | $193.05M | -$205.20M | $47.98M | -$69.76M |
| Financing cash flow | $250.00K | $35.82M | $12.99M | $214.67M | $323.10M | $78.00K | $100.19M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$52.68M | -$16.83M | -$28.36M | -$15.78M | -$19.55M | -$21.54M | -$31.70M | -$24.98M | -$24.90M | $24.81M | -$27.68M | -$23.00M |
| Capital expenditures | $0 | $459.00K | $246.00K | $378.00K | $91.00K | $14.00K | $1.92M | $4.58M | $610.00K | $1.45M | $755.00K | $682.00K |
| Free cash flow | -$52.68M | -$17.29M | -$28.61M | -$16.16M | -$19.64M | -$21.55M | -$33.62M | -$29.56M | -$25.51M | $23.35M | -$28.43M | -$23.68M |
Frequently Asked Questions About GBIO
What is Generation Bio's annual revenue?
Generation Bio reported revenue of $19.89M for the fiscal year ended Dec 31, 2024.
How fast is Generation Bio's revenue growing?
Revenue was up 236.9% for the fiscal year ended Dec 31, 2024 compared with the year before.
Is Generation Bio profitable?
No. Generation Bio reported net income of -$131.67M for the fiscal year ended Dec 31, 2024, with a net margin of -661.9%.
How much free cash flow does GBIO generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$88.56M minus capital expenditures of $2.40M produced free cash flow of -$90.96M.
How much debt does Generation Bio have?
The balance sheet dated Dec 31, 2024 reported short-term debt of $13.01M and cash and equivalents of $76.30M.
GBIO pages: Overview, Financials